Adaptive Biotechnologies Corporation (ADPT)

Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases....

A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive's proprietary TCR-antigen datasets for research ...

SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...

SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) stock is trading lower on Friday, despite no company-specific news, likely reacting to Natera Inc.'s (NASDAQ: NTRA) acquisition of cancer diagnostic...

SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...

Campbell and CO Investment Adviser LLC trimmed its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 76.7% in the second quarter, according to its most recent 13F filing with the Secu...

SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...

Adaptive Biotechnologies Corporation ( ADPT ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Karina Calzadilla - Vice President of Investor Relations Chad Robins - Co-Founder,...

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its ...